Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04731233 · ClinicalTrials.gov registry record · Phase 4
Efficacy of PRGF Supplementation After TMJ Arthrocentesis in Patients With TMJ Osteoarthritis
A Phase 4 study, sponsored by University of Florida.
- Terminated
- Registry status
- Phase 4
- Development phase
- 5
- Enrollment target
NCT04731233 is a Phase 4 study that was terminated before completion, run by University of Florida. The registered enrollment target is 5 participants.
The verdict
NCT04731233, a Phase 4 study, was terminated before completion, sponsored by University of Florida.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 5 participants
- Enrollment target
Study Summary
Temporomandibular joint (TMJ) osteoarthritis (OA) affects articulating tissues secondary to inflammation resulting in intracapsular pain. This prospective, double-blind randomized clinical trial will evaluate the relative efficacy of TMJ arthrocentesis with a supplementation of platelet-rich growth factors (PRGF) compared to TMJ arthrocentesis with a steroid supplementation (a known effective therapy) for patients with TMJ OA.
Interventions
- DRUG Triamcinolone Acetonide
- BIOLOGICAL Plasma Rich in Growth Factor (PRGF) Supplementation
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2021-03-30 |
| Est. Completion | 2024-02-21 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04731233
The ClinicalTrials.gov registry entry for NCT04731233 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 5 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Florida, which has 1,106 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Triamcinolone Acetonide is the first listed.
NCT04731233 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04731233 about?
NCT04731233 is a clinical study titled "Efficacy of PRGF Supplementation After TMJ Arthrocentesis in Patients With TMJ Osteoarthritis". Temporomandibular joint (TMJ) osteoarthritis (OA) affects articulating tissues secondary to inflammation resulting in intracapsular pain. This prospective, double-blind randomized clinical trial will evaluate the relative efficacy of TMJ arthrocentesis with a supplementation of platelet-rich growth ...
What is the current status of trial NCT04731233?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 5 participants. The study started on 2021-03-30. Estimated completion is 2024-02-21.
What interventions are being tested in trial NCT04731233?
The interventions under investigation include: Triamcinolone Acetonide (DRUG), Plasma Rich in Growth Factor (PRGF) Supplementation (BIOLOGICAL).
Who is sponsoring clinical trial NCT04731233?
This trial is sponsored by University of Florida, which has 1,106 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.